JP2022538228A5 - - Google Patents
Info
- Publication number
- JP2022538228A5 JP2022538228A5 JP2021576576A JP2021576576A JP2022538228A5 JP 2022538228 A5 JP2022538228 A5 JP 2022538228A5 JP 2021576576 A JP2021576576 A JP 2021576576A JP 2021576576 A JP2021576576 A JP 2021576576A JP 2022538228 A5 JP2022538228 A5 JP 2022538228A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- linear
- compound
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181952 | 2019-06-24 | ||
| EP19181952.3 | 2019-06-24 | ||
| PCT/EP2020/067451 WO2020260252A1 (en) | 2019-06-24 | 2020-06-23 | New macrocyclic compounds and derivatives as egfr inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538228A JP2022538228A (ja) | 2022-09-01 |
| JP2022538228A5 true JP2022538228A5 (cg-RX-API-DMAC7.html) | 2023-06-26 |
| JP7590996B2 JP7590996B2 (ja) | 2024-11-27 |
Family
ID=67003267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576576A Active JP7590996B2 (ja) | 2019-06-24 | 2020-06-23 | Egfr阻害剤としての新たな大環状化合物および誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12522615B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986564A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7590996B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114007698B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020260252A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220114615A (ko) | 2019-12-16 | 2022-08-17 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Egfr 키나제의 분해를 억제 및 유도하는 화합물 |
| CN113880804A (zh) * | 2020-07-01 | 2022-01-04 | 微境生物医药科技(上海)有限公司 | 新型苯并咪唑化合物 |
| CN114163454B (zh) * | 2020-09-11 | 2026-01-02 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| CN114057771B (zh) * | 2020-12-03 | 2023-10-03 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| CN114656482B (zh) * | 2020-12-23 | 2025-10-17 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| CN114907379B (zh) * | 2021-02-06 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的大环化合物 |
| CN116761603A (zh) * | 2021-02-06 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途 |
| US20240166665A1 (en) * | 2021-03-02 | 2024-05-23 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
| WO2022204544A1 (en) * | 2021-03-26 | 2022-09-29 | Theseus Pharmaceuticals, Inc. | Macrocyclic egfr inhibitors for the treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| AU2022272190A1 (en) * | 2021-05-11 | 2023-11-23 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2022242712A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的大环化合物及包含该化合物的组合物及其用途 |
| CN115433207A (zh) * | 2021-06-03 | 2022-12-06 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| JP2024527464A (ja) * | 2021-06-30 | 2024-07-25 | アキリオン アーベー | 大環状tak1阻害剤 |
| WO2023001069A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 大环酰胺类化合物及其应用 |
| AU2022402875A1 (en) * | 2021-11-30 | 2024-06-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Compound containing cycloalkyl or haloalkyl |
| WO2023205595A2 (en) * | 2022-04-20 | 2023-10-26 | Celyn Therapeutics, Inc | Egfr inhibitors in cancer treatment |
| CN117024443A (zh) * | 2022-05-09 | 2023-11-10 | 元启(苏州)生物制药有限公司 | Egfr抑制剂及其用途 |
| CN119522227A (zh) * | 2022-07-21 | 2025-02-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| WO2024016986A1 (zh) | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| TW202416963A (zh) * | 2022-09-02 | 2024-05-01 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Egfr抑制劑及其用途 |
| WO2024078263A1 (zh) * | 2022-10-09 | 2024-04-18 | 药雅科技(上海)有限公司 | 大环杂环类化合物作为egfr抑制剂的制备及其应用 |
| CN117229300A (zh) * | 2023-03-12 | 2023-12-15 | 药雅科技(上海)有限公司 | Egfr抑制剂的制备及其应用 |
| WO2024099400A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| WO2024099402A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| AR131026A1 (es) * | 2022-11-10 | 2025-02-12 | Beigene Ltd | Compuestos para la degradación de la egfr quinasa |
| CN118324778B (zh) * | 2023-04-25 | 2026-08-11 | 苏州共康医药科技有限公司 | 第四代egfr抑制剂 |
| WO2024246838A1 (en) * | 2023-05-31 | 2024-12-05 | Beigene Switzerland Gmbh | Compounds for the degradation of egfr kinase |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
| EA200400595A1 (ru) | 2001-11-09 | 2004-10-28 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| WO2005079791A1 (en) | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| US20110071130A1 (en) | 2006-05-08 | 2011-03-24 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| US20150152083A1 (en) * | 2012-06-06 | 2015-06-04 | Irm Llc, A Delaware Limited Liability Company | Compounds and Compositions for Modulating EGFR Activity |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| ES2639717T3 (es) * | 2013-02-07 | 2017-10-30 | Merck Patent Gmbh | Derivados de piridazinona macrocíclicos |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| IL291000B2 (en) | 2014-03-20 | 2024-04-01 | Capella Therapeutics Inc | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| WO2016176473A1 (en) | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| WO2016185333A1 (en) | 2015-05-15 | 2016-11-24 | Novartis Ag | Methods for treating egfr mutant cancers |
| HK1252693A1 (zh) | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| KR102670695B1 (ko) | 2015-09-18 | 2024-06-05 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
| ES2911888T3 (es) | 2015-09-18 | 2022-05-23 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| US11083793B2 (en) | 2016-12-13 | 2021-08-10 | Health Research, Inc. | Epidermal growth factor receptor (EGFR) targeted photosensitizers |
-
2020
- 2020-06-23 US US17/621,420 patent/US12522615B2/en active Active
- 2020-06-23 JP JP2021576576A patent/JP7590996B2/ja active Active
- 2020-06-23 CN CN202080045795.1A patent/CN114007698B/zh active Active
- 2020-06-23 WO PCT/EP2020/067451 patent/WO2020260252A1/en not_active Ceased
- 2020-06-23 EP EP20734188.4A patent/EP3986564A1/en active Pending